title: Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics.
abstract: Lyme borreliosis (LB) is a multisystem infectious disease with a growing burden in many parts of North America, Asia and Europe. Persistent infection of LB can usually be treated effectively with antibiotic therapy, but it may be followed by post-treatment Lyme disease syndrome. Therefore, it is important to begin with treatment in the early phase of the disease. Vaccination shows potential as the most effective way of preventing LB and reducing its burden in these continents. It is concluded that there is a need for continuous effort in research from all perspectives on LB, especially regarding prevention with novel vaccines, their development, clinical efficacy and cost-effectiveness. This review may help to further develop (cost-) effective strategies for prevention and control of the disease to reduce its burden and achieve population-wide health benefits.
authors.affiliation: a 1 Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands.|b 2 Institute of Science Healthy Aging & healthcaRE (SHARE), University Medical Center Groningen (UMCG), Groningen, The Netherlands.
authors.forename: Renata
authors.initials: R
authors.lastname: Šmit
authors.affiliation: a 1 Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands.|b 2 Institute of Science Healthy Aging & healthcaRE (SHARE), University Medical Center Groningen (UMCG), Groningen, The Netherlands.
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Postma
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D001208:Asia / Q000453:epidemiology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D025065:Borrelia burgdorferi / Q000276:immunology*; D003362:Cost-Benefit Analysis; D005060:Europe / Q000453:epidemiology; D006801:Humans; D018884:Ixodes / Q000382:microbiology; D008074:Lipoproteins / Q000276:immunology; D008193:Lyme Disease / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D022123:Lyme Disease Vaccines / Q000009:adverse effects / Q000191:economics / Q000276:immunology*; D009656:North America / Q000453:epidemiology; D014611:Vaccination / Q000009:adverse effects* / Q000191:economics
chemical_list: D000942:Antigens, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; D022123:Lyme Disease Vaccines; C072045:OspA protein; C079616:OspC protein
keywords: Borrelia burgdorferi; Lyme borreliosis; Lyme disease; cost-effectiveness; health economics; treatment; vaccines